<--- Back to Details
First PageDocument Content
Medicine / Clinical medicine / Immunology / Immunosuppressants / Monoclonal antibodies / RTT / Biotechnology / Abatacept / Infliximab / TNF inhibitor / Arthritis / Rheumatoid arthritis
Date: 2015-10-20 13:17:44
Medicine
Clinical medicine
Immunology
Immunosuppressants
Monoclonal antibodies
RTT
Biotechnology
Abatacept
Infliximab
TNF inhibitor
Arthritis
Rheumatoid arthritis

FEBRUARY 2015 TABLE OF CONTENTS INTRODUCTION

Add to Reading List

Source URL: www.abirisk.eu

Download Document from Source Website

File Size: 356,68 KB

Share Document on Facebook

Similar Documents

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

DocID: 1rrNB - View Document

Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis rev. 2

Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis rev. 2

DocID: 1rmwo - View Document

EAP Reimbursement Criteria for Frequently Requested Drugs

EAP Reimbursement Criteria for Frequently Requested Drugs

DocID: 1rhhE - View Document

UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol

UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol

DocID: 1rakB - View Document

TABLE OF CONTENTS  INTRODUCTION 2

TABLE OF CONTENTS INTRODUCTION 2

DocID: 1qY7G - View Document